Why BlossomHill Therapeutics, Inc.’s (BLSM) Stock Is Down 7.21%
As of Wednesday, September 30, BlossomHill Therapeutics, Inc.’s BLSM share price has dipped by 7.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: BlossomHill Therapeutics, Inc. (BLSM)
BlossomHill Therapeutics, Inc. BLSM
$18.59
-0.05
-0.27%
October 1, 2026 4:00:00 PM
EST
Volume: 152,581
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Commentary & Analysis
Why BlossomHill Therapeutics, Inc.’s (BLSM) Stock Is Down 5.01%
As of Thursday, September 24, BlossomHill Therapeutics, Inc.’s BLSM share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why BlossomHill Therapeutics, Inc.’s (BLSM) Stock Is Down 5.17%
As of Wednesday, September 23, BlossomHill Therapeutics, Inc.’s BLSM share price has dipped by 5.17%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why BlossomHill Therapeutics, Inc.’s (BLSM) Stock Is Up 6.84%
As of Monday, September 21, BlossomHill Therapeutics, Inc.’s BLSM share price has surged by 6.84%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why BlossomHill Therapeutics, Inc.’s (BLSM) Stock Is Up 10.96%
As of Wednesday, September 16, BlossomHill Therapeutics, Inc.’s BLSM share price has surged by 10.96%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $592.5 | $560.7 | 39% |
|
| Shares Out (Mil) | 2.7 | 42.3 | 10% |
|
| Institutional Ownership | 42.8% | 84.3% | 18% |
|
| Float (Mil) | 17.7 | 45.7 | 27% |
|
| Beta | na | 0.72 | na |
|
| Avg Daily Volume (000s) | 292 | 392 | 48% |
|
| Price Change (52-week) |
na | 60.8% | na |
|
| Growth | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 5.7% | na |
|
| Net Income (5yr) | na | (1.5%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.898) | ($5.095) | ($3.955) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (89.7%) | (79.5%) | (83.2%) | |
| Financials | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $326 | na |
|
| Net Income (TTM) (Mil) | ($82) | ($11) | 13% |
|
| EPS (TTM) | ($31.827) | ($0.700) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($71) | ($7) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($62) | $6 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $22 | $6 | 33% |
|
| Enterprise Value (Q1) (Mil) | $959 | $493 | 40% |
|
| Valuation | BLSM | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.34 | na |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 2.5% | na |
|
| ROA | (131.5%) | (22.4%) | 4% |
|
| ROE | 93.4% | (23.8%) | 96% |
|
| Liabilities to Assets | 33.9% | 32.6% | 25% |
|
| F-Score | 1 | 3 | na |
|
BlossomHill Therapeutics, Inc. did not pass any screens on 9/30/2026.
